


Partnering with Astellas

Turning innovative science into VALUE for patients



Astellas is a specialty global pharmaceutical company operating in more than 70 countries, with cutting-edge research and development (R&D) and commercialization capabilities around the world.

We focus on accelerating the discovery, development and commercialization of ground-breaking innovations that could redefine expectations of care for difficult-to-treat diseases.



>10 **R&D hubs**
including world-leading cell and gene therapy production facilities

>5 **Manufacturing hubs**
including sites within our network of expert partners and acquired entities

Collaborations are key to our success


We seek ambitious partners that share our vision, enhance the potential competitive advantages of our science and complement our areas of expertise.

We are growing our broad pipeline and our expertise in emerging areas of discovery research, including immuno-oncology, genetic regulation, mitochondria, blindness & regeneration and targeted protein degradation, pursuing innovation partnerships across:

- Modulation of tumor microenvironment
- Highly tumor-specific antigen/markers
- Novel target protein degrader platforms
- Engineered antibody/biologics (novel engagers, bi-specific ADCs)

- Disease-state/cell-type specific gene expression for AAV
- Technologies to avoid pre-existing immunity/allow redosing of AAV
- Non-viral approaches including mRNA
- Novel AAV capsid delivery technology

- Biomaterials to enhance cell engraftment
- Novel technology for cell engineering and production
- iPSC technologies for differentiation, maturation and functionality



- Ophthalmology, muscle, and CNS diseases including autophagy and mitochondrial disease, spanning reprogramming and regeneration approaches
- Modalities include small molecules, E3 ligase focus, gene and cell therapies

- Tissue/disease-site specific T-Reg, macrophage
- Modulation of innate immune response
- Inflammasome directed approaches

- In vivo cell direct reprogramming
- Chronobiology

Our approach

Maximizing our innovation potential

We take a long-term strategic view in creating and building win-win partnerships. Our partnering efforts and resources are focused on areas of high unmet need where we can deliver the greatest value to patients.



Innovative global company:
Experience • Expertise • Scale



We offer a unique combination of global scale and entrepreneurial spirit



Entrepreneurial spirit:
Agility • Tenacity • Flexibility

Our expert teams are championing new and more nimble ways of collaborating to:

- Make smarter decisions faster
- +
- Enhance shared learning
- +
- Enable us and our partners to work flexibly



So together, we can accelerate innovative science for patients in need

The success of your innovation is as important to us as it is to you. Our passionate and driven teams work with each partner to build creative scopes and structures to accelerate our shared success.

Building flexible deal structures

Each partnership is **unique**, which is why we develop tailored approaches that are **fit for every deal** regardless of development stage.

Our offering includes a wide spectrum of investments and deals such as:



Public-private partnerships



R&D collaborations




In- and out-licensing



Mergers and acquisitions

Being a good partner



Together, we can define entirely new ways to treat and potentially cure some of the most challenging diseases. Partner with us as we seek to transform the lives of the patients we serve.

If you share our passion for innovation and delivering meaningful **VALUE** to patients, we would love to hear from you. You can reach us at www.astellas.com/en/partnering/register-form